Sarah A Beckman1,2, Naosumi Sekiya3,4,2, William C W Chen3,5,2, Logan Mlakar2, Kimimassa Tobita6, Johnny Huard3,1,5,2. 1. Department of Pathology, University of Pittsburgh, Pittsburgh, PA, U.S.A. 2. Stem Cell Research Center, University of Pittsburgh, Pittsburgh, PA, U.S.A. 3. Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, U.S.A. 4. Department of Surgery, University of Pittsburgh, Pittsburgh, PA, U.S.A. 5. Department of BioEngineering, University of Pittsburgh, Pittsburgh, PA, U.S.A. 6. Department of Developmental Biology, University of Pittsburgh, Pittsburgh, PA, U.S.A.
Abstract
INTRODUCTION: Since myoblasts have been limited by poor cell survival after cellular myoplasty, the major goal of the current study was to determine whether improving myoblast survival with an antioxidant could improve cardiac function after the transplantation of the myoblasts into an acute myocardial infarction. BACKGROUND: We previously demonstrated that early myogenic progenitors such as muscle-derived stem cells (MDSCs) exhibited superior cell survival and improved cardiac repair after transplantation into infarcted hearts compared to myoblasts, which we partially attributed to MDSC's higher antioxidant levels. AIM: To determine if antioxidant treatment could increase myoblast survival, subsequently improving cardiac function after myoblast transplantation into infarcted hearts. MATERIALS AND METHODS: Myoblasts were pre-treated with the antioxidant N-acetylcysteine (NAC) or the glutathione depleter, diethyl maleate (DEM), and injected into infarcted murine hearts. Regenerative potential was monitored by cell survival and cardiac function. RESULTS: At early time points, hearts injected with NAC-treated myoblasts exhibited increased donor cell survival, greater cell proliferation, and decreased cellular apoptosis, compared to untreated myoblasts. NAC-treated myoblasts significantly improved cardiac contractility, reduced fibrosis, and increased vascular density compared to DEM-treated myoblasts, but compared to untreated myoblasts, no difference was noted. DISCUSSION: While early survival of myoblasts transplanted into infarcted hearts was augmented by NAC pre-treatment, cardiac function remained unchanged compared to non-treated myoblasts. CONCLUSION: Despite improving cell survival with NAC treated myoblast transplantation in a MI heart, cardiac function remained similar to untreated myoblasts. These results suggest that the reduced cardiac regenerative potential of myoblasts, when compared to MDSCs, is not only attributable to cell survival but is probably also related to the secretion of paracrine factors by the MDSCs.
INTRODUCTION: Since myoblasts have been limited by poor cell survival after cellular myoplasty, the major goal of the current study was to determine whether improving myoblast survival with an antioxidant could improve cardiac function after the transplantation of the myoblasts into an acute myocardial infarction. BACKGROUND: We previously demonstrated that early myogenic progenitors such as muscle-derived stem cells (MDSCs) exhibited superior cell survival and improved cardiac repair after transplantation into infarcted hearts compared to myoblasts, which we partially attributed to MDSC's higher antioxidant levels. AIM: To determine if antioxidant treatment could increase myoblast survival, subsequently improving cardiac function after myoblast transplantation into infarcted hearts. MATERIALS AND METHODS: Myoblasts were pre-treated with the antioxidant N-acetylcysteine (NAC) or the glutathione depleter, diethyl maleate (DEM), and injected into infarctedmurine hearts. Regenerative potential was monitored by cell survival and cardiac function. RESULTS: At early time points, hearts injected with NAC-treated myoblasts exhibited increased donor cell survival, greater cell proliferation, and decreased cellular apoptosis, compared to untreated myoblasts. NAC-treated myoblasts significantly improved cardiac contractility, reduced fibrosis, and increased vascular density compared to DEM-treated myoblasts, but compared to untreated myoblasts, no difference was noted. DISCUSSION: While early survival of myoblasts transplanted into infarcted hearts was augmented by NAC pre-treatment, cardiac function remained unchanged compared to non-treated myoblasts. CONCLUSION: Despite improving cell survival with NAC treated myoblast transplantation in a MI heart, cardiac function remained similar to untreated myoblasts. These results suggest that the reduced cardiac regenerative potential of myoblasts, when compared to MDSCs, is not only attributable to cell survival but is probably also related to the secretion of paracrine factors by the MDSCs.
Authors: Hideki Oshima; Thomas R Payne; Kenneth L Urish; Tetsuro Sakai; Yiqun Ling; Burhan Gharaibeh; Kimimasa Tobita; Bradley B Keller; James H Cummins; Johnny Huard Journal: Mol Ther Date: 2005-08-25 Impact factor: 11.454
Authors: Kenneth L Urish; Joseph B Vella; Masaho Okada; Bridget M Deasy; Kimimasa Tobita; Bradley B Keller; Baohong Cao; Jon D Piganelli; Johnny Huard Journal: Mol Biol Cell Date: 2008-11-12 Impact factor: 4.138
Authors: Yao Liang Tang; Yi Tang; Y Clare Zhang; Keping Qian; Leping Shen; M Ian Phillips Journal: J Am Coll Cardiol Date: 2005-10-04 Impact factor: 24.094
Authors: Martin Rodriguez-Porcel; Olivier Gheysens; Ramasamy Paulmurugan; Ian Y Chen; Karen M Peterson; Jürgen K Willmann; Joseph C Wu; Xiangyang Zhu; Lilach O Lerman; Sanjiv S Gambhir Journal: Mol Imaging Biol Date: 2009-12-15 Impact factor: 3.488